Marshall Edwards, Inc.(Nasdaq:MSHL) announced the publication of results from a pre-clinical study of its investigational compound NV-128, that’s showing activity in chemotherapy-resistant ovarian cancer stem cells. MSH stock gained over 130% on 150X 10day average volume as of 10 a.m. on July 27th.
Marshall Edwards Announces Publication of Pre-Clinical Study Showing Activity in Chemotherapy-Resistant Ovarian Cancer Stem Cells
SAN DIEGO, July 27, 2011 /PRNewswire/ — Marshall Edwards, Inc.(Nasdaq:MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced the publication of results from a pre-clinical study of NV-128 showing activity in chemotherapy-resistant ovarian cancer stem cells. NV-128 is the prodrug of the Company’s investigational compound and lead mitochondrial inhibitor drug candidate, NV-344. The publication, entitled “Targeting the mitochondria activates two independent cell death pathways in the ovarian cancer stem cells,” is available on the Molecular Cancer Therapeutics website and scheduled to print in the August issue of the journal. An abstract can be found at http://www.marshalledwardsinc.com/our-programs/scientific-publications
Marshall Edwards Inc.
11975 El Camino Real
Suite 101
San Diego, CA 92130
United States – Map
Phone: 858-792-6300
http://www.marshalledwardsinc.com
Marshall Edwards was formed to develop novel cancer therapeutics based on the central design of naturally occurring compounds called isoflavones. These compounds are believed to interact with specific enzyme targets resulting in inhibition of tumor cell metabolism – a function critical for the survival of cancer cells.
Marshall Edwards’ lead programs focus on two groups of small molecules with related but distinct mechanisms of action. The first and most advanced is our NADH oxidase program, a family of compounds that includes lead candidate NV-143. The second is our novel mitochondrial inhibitor program, which includes NV-344. Both programs are expected to advance into the clinic in 2011.